Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Intra-articular implantation of collagen scaffold carriers is safe in both native and arthrofibrotic rabbit knee joints
Walker, Justin A. , Ewald, Timothy J., Lewallen, Eric A. , Wijnen, André J. van , Hanssen, Arlen D. , Morrey, B.F. , Morrey, Mark E. , Abdel, Matthew P. , Sánchez‐Sotelo, Joaquín , van Wijnen, Andre J

Mayo Clinic

Bone & Joint Research | March 28, 2017 | Volume: 6 | Issue: 3 | Pages: 162-171

10.1302/2046-3758.63.bjr-2016-0193 | PMID 28347978 Get It

Objectives Sustained intra-articular delivery of pharmacological agents is an attractive modality but requires use of a safe carrier that would not induce cartilage damage or fibrosis. Collagen scaffolds are widely available and could be used intra-articularly, but no investigation has looked at the safety of collagen scaffolds within synovial joints. The aim of this study was to determine the safety of collagen scaffold implantation in a validated in vivo animal model of knee arthrofibrosis. Materials and Methods A total of 96 rabbits were randomly and equally assigned to four different groups: arthrotomy alone; arthrotomy and collagen scaffold placement; contracture surgery; and contracture surgery and collagen scaffold placement. Animals were killed in equal numbers at 72 hours, two weeks, eight weeks, and 24 weeks. Joint contracture was measured, and cartilage and synovial samples underwent histological analysis. Results Animals that underwent arthrotomy had equivalent joint contractures regardless of scaffold implantation (-13.9° versus -10.9°, equivalence limit 15°). Animals that underwent surgery to induce contracture did not demonstrate equivalent joint contractures with (41.8°) or without (53.9°) collagen scaffold implantation. Chondral damage occurred in similar rates with (11 of 48) and without (nine of 48) scaffold implantation. No significant difference in synovitis was noted between groups. Absorption of the collagen scaffold occurred within eight weeks in all animals Conclusion Our data suggest that intra-articular implantation of a collagen sponge does not induce synovitis or cartilage damage. Implantation in a native joint does not seem to induce contracture. Implantation of the collagen sponge in a rabbit knee model of contracture may decrease the severity of the contracture. Cite this article: J. A. Walker, T. J. Ewald, E. Lewallen, A. Van Wijnen, A. D. Hanssen, B. F. Morrey, M. E. Morrey, M. P. Abdel, J. Sanchez-Sotelo. Intra-articular implantation of collagen scaffold carriers is safe in both native and arthrofibrotic rabbit knee joints. Bone Joint Res 2016;6:162–171. DOI: 10.1302/2046-3758.63.BJR-2016-0193.
Bilateral Labyrinthine and Internal Auditory Canal Enhancement in an Infant With Severe Labyrinthine Dysplasia: A Previously Unreported Phenomenon
Anzalone, C. Lane , Ho, Mai‐Lan , Patel, Neil S. , Schimmenti, Lisa A. , DeJong, Melissa D., Carlson, Matthew L. , Anzalone, Charles L, Ho, Mai Lan, Schimmenti, Lisa A , Ho, Mai-Lan

Mayo Clinic

Otology & Neurotology | March 25, 2017 | Volume: 38 | Issue: 5 | Pages: e21-e25

10.1097/mao.0000000000001392 | PMID 28346292 Get It

Objective: To describe a novel case of congenital profound bilateral sensorineural hearing loss in a patient with bilateral nodular internal auditory canal and labyrinthine enhancement and temporal bone dysplasia. Patients: A 76-day-old female was referred to the authors’ center for evaluation of congenital deafness. Behavioral observations and objective audiometric evaluation demonstrated bilateral profound sensorineural hearing loss and a comprehensive multidisciplinary evaluation identified compound heterozygous pathogenic variants in MYO7A , a gene associated with Usher Syndrome Type 1B or DFNB2. Computed tomography and contrast-enhanced magnetic resonance imaging studies demonstrated bilateral temporal bone anomalies with unique middle and inner ear malformations, as well as unique contrast enhancement in the membranous labyrinth, internal auditory canals, and cranial nerves, which have not been previously described with MYO7A variants. Interventions: Given the potential risk for progressive bilateral labyrinthitis ossificans, bilateral simultaneous cochlear implantation was performed at 4 months of age. Main Outcome Measures: Subsequent audiologic follow up after implantation shows significantly improved access to auditory information and increased vocalizations. At last testing, speech and language skills for both receptive and expressive language abilities were found to be commensurate with her chronological age. Conclusion: We report a novel presentation and imaging findings of congenital bilateral profound sensorineural hearing loss in a patient with nodular internal auditory canal and labyrinthine enhancement and coexisting inner ear dysplasia. Despite the multiple radiologic abnormalities, the patient has demonstrated good benefit from cochlear implantation. Future study of rare variants of congenital deafness, such as this, is critical toward defining new disease processes and determining optimal treatment.
Special issue on Quantitative Ultrasound-Based Tissue Characterization - Call for Papers
Lavarello, Roberto , Urban, Matthew W.

Mayo Clinic

IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control | March 24, 2017 | Volume: 62 | Issue: 9 | Pages: c5-c5

10.1109/tuffc.2015.7272471 Get It

Utility of PET/CT After Cryoablation for Early Identification of Local Tumor Progression in Osseous Metastatic Disease
Packard, Annie T. , Callstrom, Matthew R. , Atwell, Thomas D. , Schmit, Grant D. , Schmitz, John J. , Packard, Ann T., Hunt, Christopher H. , Kurup, A. Nicholas , Broski, Stephen M. , Morris, Jonathan M.

Mayo Clinic

American Journal of Roentgenology | March 23, 2017 | Volume: 208 | Issue: 6 | Pages: 1342-1351

10.2214/ajr.16.17222 | PMID 28333548 Get It

Arteriovenous Lesions of the Internal Auditory Canal
Anzalone, C. Lane , Lane, John I. , Link, Michael J., Carlson, Matthew L. , Anzalone, Charles L, Link, Michael J.

Mayo Clinic

Otology & Neurotology | March 23, 2017 | Volume: 38 | Issue: 5 | Pages: e46-e49

10.1097/mao.0000000000001401 | PMID 28333777 Get It

Objective: To describe a unique case of an asymptomatic arteriovenous lesion of the internal auditory canal (IAC) and present the associated imaging findings. Methods: Retrospective case report and review of the literature. Results: A 55-year-old man presented for further evaluation of a left-sided sudden sensorineural hearing loss that occurred 8 years earlier. Careful review of outside serial magnetic resonance (MR) imaging revealed a contralateral, ill-defined right-sided IAC mass with low T2 signal and subtle peripheral enhancement on postcontrast T1-weighted sequencing. The patient had no history of right-sided otologic symptoms. Subsequent dedicated IAC MR imaging confirmed the presence of a space-occupying lesion adjacent to a complexity of vasculature. The presence of prominent flow voids, paucity of avid enhancement on previous studies, and marked signal within the lesion on time-of-flight MR angiography and MR venography was consistent with the diagnosis of a solitary arteriovenous lesion of the IAC. There was no radiological evidence of recent or remote parenchymal or subarachnoid hemorrhage or stroke. Conclusion: We report a novel case of an occult asymptomatic IAC arteriovenous lesion. Vascular anomalies confined to the IAC are rare. To date, there have been only four reports in the literature of IAC arteriovenous lesions and our case is the first to present asymptomatically. A high index of suspicion and dedicated imaging is required to identify and accurately diagnose these lesions to guide appropriate counseling and potential intervention.
Psychosocial distress in lymphoma survivors at 3 years’ follow-up.
Allmer, Cristine, Ansell, Stephen M. , Yost, Kathleen J. , Thompson, Carrie A. , Rosenthal, Allison , Maurer, Matthew J. , Farooq, Umar , Habermann, Thomas M. , Link, Brian K. , Witzig, Thomas E. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 5_suppl | Pages: 193-193

10.1200/jco.2017.35.5_suppl.193 Get It

193 Background: National standards recommend distress screening as part of cancer care. While many patients report improved quality of life after cancer treatment concludes there remains a population who experience ongoing anxiety and depressive symptoms. We sought to describe psychosocial distress in lymphoma survivors and frequency of visits to mental health providers (MHP). Methods: Lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource and systematically followed. Brief Profile of Mood States (POMS) and State Trait Anxiety Inventory (STAI) were administered 3 yrs after diagnosis. Lower scores on POMS indicated more distress. A higher score on STAI indicated more anxiety, and a score ≥ 40 was considered clinically significant. Pts were asked if they ever saw a MHP due to their lymphoma. Results: Between 2002-2012, 2465 lymphoma pts age 18-91 (10% 18-40, 54% 41-65, and 36% > 65) were enrolled, met survivor definition, and completed 3-yr POMS and STAI questionnaires. 57% were male. 40% had aggressive and 60% had indolent lymphoma. The median score on STAI 1 (state) was 32 (range 20-76) and on STAI 2 (trait) was 31 (range 20-77). Median POMS total mood disturbance (TMD) score was 88 (range 1-100). 8% of pts reported seeing a MHP. 609 pts (25%) had clinically significant anxiety by STAI 1, 73 (12%) of whom saw a MHP. Those who reported clinically significant anxiety on STAI were more likely to be younger, unemployed, unmarried, and less likely to have seen a MHP. Anxiety levels were similar between those with aggressive lymphoma and indolent lymphoma regardless of treatment. Higher distress levels, measured by TMD, were more often reported by those who were unemployed or over age 65 while there was no association with lymphoma subtype, marital status, or choice of therapy. Conclusions: Clinically significant anxiety was reported in 25% of 3-yr survivors of lymphoma and was associated with younger age, unmarried status, and unemployment. Higher distress levels were associated with older age, and unemployment. However, only 8% of our cohort was seen by a MHP. Identifying distress and appropriately referring to a MHP is important for the optimal care of lymphoma survivors.
Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database.
Salem, Mohamed E. , Yin, Jun , Renfro, Lindsay A. , Seymour, Michel , Bokemeyer, Carsten , Heinemann, Volker , Gramont, Aimery de , Weinberg, Benjamin A. , Maughan, Tim , Adams, Richard , Cutsem, Eric Van , Falcone, Alfredo , Tebbutt, Niall C. , Díaz‐Rubio, Eduardo , Aranda, Enrique , Grothey, Axel , Marshall, John L , Sargent, Daniel J. , Seymour, Matthew T

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 675-675

10.1200/jco.2017.35.4_suppl.675 Get It

675 Background: Recent retrospective analysis of CALGB/SWOG 80405 showed that left-sided colon cancers (LCC) respond differently to biological therapy compared with right-sided tumors. However, differences between rectal cancers (RC) and LCC remain undefined. Herein, we report our exploration of differences between these two groups. Methods: Individual patient data from 4182 patients (pts) with metastatic colorectal cancers, enrolled onto 8 first-line randomized trials, were pooled. Only pts with tumor locations that were clearly defined as LCC (splenic flexure to sigmoid) or RC were included in this analysis. Differences in pt characteristics and disease factors according to LCC vs. RC were identified. The prognostic effect of primary tumor location on OS and PFS was quantified via multivariable Cox proportional hazards modeling stratified by treatment arm within each study and adjusting for age, sex, performance status, and prior surgery. Results: In total, 2,479 (59%) pts with LCC and 1,703 (41%) pts with RC were identified. Pts with RC, compared with LCC, were more likely to be male (68% vs. 62%, p < 0.001), have lung metastases (mets) (56% vs. 37%, p < 0.001), and have 2 or more metastatic sites (64% vs. 60%, p < 0.02), whereas pts with LCC were more likely to have liver mets (84% vs. 76%, p < 0.001). RC had a greater frequency of KRAS mutations (41% vs. 37%, p = 0.04) than LCC but there were no differences in the frequency of BRAF mutations (5% vs. 4%, p = 0.2). In multivariable analysis, no differences in OS or PFS were observed between pts with LCC vs. RC. While risk of death did not differ by primary tumor location, across all pts with LCC or RC, those with liver mets had a 17% increased risk of death compared to those with lung mets (HR = 1.17, p = 0.03) after adjusting for effects of other variables. Forthcoming prognostic analysis of LCC vs. RC within grouped backbone treatments (e.g., FOLFOX and FOLFIRI) is underway. Conclusions: Tumors arising in the rectum may carry clinical and molecular features that are distinct from LCC. Further investigations are warranted to determine whether RC should be treated with the same chemo backbone and biological therapy as LCC.
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.
Wolin, Edward M. , Chasen, Beth, Kulke, Matthew H. , Caplin, Martyn , Baum, Richard P. , Kunz, Pamela L. , Hobday, Timothy J. , Hendifar, Andrew , Öberg, Kjell E., Sierra, Maribel Lopera , Kwekkeboom, Dik J., Ruszniewski, Philippe, Krenning, Eric P. , Strosberg, Jonathan , Bushnell, David

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 348-348

10.1200/jco.2017.35.4_suppl.348 Get It

348 Background: Neuroendocrine tumor progression is associated with decline in quality of life, both due to tumor and hormone-related symptoms. The Phase III NETTER-1 trial randomized patients with advanced, progressive midgut NETs to receive treatment with 177Lu-DOTATATE (177Lu; Lutathera) versus high-dose (60 mg) Octreotide LAR (Oct). EORTC questionnaires C30 and GINET21 were assessed during the trial in order to determine the impact of treatment on health-related quality of life (HRQoL). Methods: Patients completed EORTC QLQ-30 and QLQ-G.I.NET21 questionnaires at baseline and every 12 weeks thereafter until disease progression. Raw scores were converted to a 100-point scale and individual changes from baseline scores were assessed. Clinically relevant ( ≥ 10 point) deterioration/improvement was considered clinically significant. Results: Clinically and statistically significant improvements in QoL were observed in the 177Lu arm versus the Oct arm at certain time points in key domains of HRQoL including global health status and diarrhea. In mean, global health status improved in 28% of patients on 177Lu arm vs. 15% on Oct, and worsened in 18% of patients on 177Lu vs. 26% on Oct. Diarrhea improved in 39% of patients on 177Lu vs. 23% on Oct, and worsened in 19% of patients on 177Lu vs. 23% on Oct. There was a trend towards improvement in pain that was not statistically significant. Flushing appeared to improve compared to baseline in both arms of the study with no clear advantage to treatment with 177Lu vs. Oct. Conclusions: QoL analysis suggests benefit in important domains associated with 177Lu treatment compared to high-dose octreotide in patients with advanced midgut NETs, and confirms the treatment value of 177Lu on patient QoL, in addition to the meaningful increase in progression-free survival already reported. Clinical trial information: NCT01578239.
Total Hip Arthroplasty in Patients with Cerebral Palsy
Watts, Chad D. , Trousdale, Robert T. , Milbrandt, Todd A. , Taunton, Michael J. , Houdek, Matthew T. , Wyles, Cody C. , Taunton, Michael J , Pagnano, Mark W

Mayo Clinic

Journal of Bone and Joint Surgery | March 15, 2017 | Volume: 99 | Issue: 6 | Pages: 488-493

10.2106/jbjs.16.00528 | PMID 28291181 Get It

Background: The spasticity and increased muscle tone observed in patients with cerebral palsy can lead to hip degeneration, subluxation, and pain. Currently, there is hesitation to perform total hip arthroplasty in patients with cerebral palsy because of fears of early wear and dislocation. The purpose of this study was to review the outcomes of total hip arthroplasty in patients with cerebral palsy and to compare outcomes with those of matched patients with a diagnosis of osteoarthritis. Methods: Over a 24-year period, 39 patients undergoing a total hip arthroplasty with a diagnosis of cerebral palsy were identified. The cohort included 26 male patients (67%), and the mean patient age was 49 years. The mean follow-up was 7 years. Patients with cerebral palsy were matched 1:2 with a group of patients undergoing total hip arthroplasty for osteoarthritis. Results: There was no difference in the rate of reoperation, implant survival, or complications, specifically dislocation. Prior to the surgical procedure, all patients had severe or moderate pain, and postoperatively no patient had moderate or severe pain. Twenty-three patients had an improvement in their ability to independently walk, and all preoperative hip flexion contractures were corrected (n = 9). There was also a significant improvement (p < 0.0001) in functional Harris hip scores. Conclusions: This study refutes previous evidence showing increased risk of complications following total hip arthroplasty in patients with cerebral palsy. Total hip arthroplasty is a durable treatment option and provides clinically important pain relief and functional improvement in patients with cerebral palsy. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
A Surge in cadaveric liver donors and a national narcotic epidemic: Is there an association?
Goss, Matthew , Reese, Jeffrey C. , Kueht, Michael , Mindikoglu, Ayse L. , Sussman, Norman , Rana, Abbas , Vierling, John M., Kaplan, Bruce , Wood, Robert

Mayo Clinic

Liver Transplantation | March 14, 2017 | Volume: 23 | Issue: 5 | Pages: 698-700

10.1002/lt.24761 | PMID 28295986 Get It